Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-004954
Filing Date
2025-11-14
Accepted
2025-11-14 10:45:16
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8741
  Complete submission text file 0000902664-25-004954.txt   10646
Mailing Address 277 PARK AVE 23RD FLOOR NEW YORK NY 10172
Business Address 277 PARK AVE 23RD FLOOR NEW YORK NY 10172 2122872500
HIGHBRIDGE CAPITAL MANAGEMENT LLC (Filed by) CIK: 0000919185 (see all company filings)

EIN.: 134131516 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Subject) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87705 | Film No.: 251482556
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)